Cybin Secures U.S. Patent for CYB003 Program, Advancing Mental Health Therapeutics

Cybin Inc., a clinical-stage neuropsychiatry company, has achieved a milestone with the issuance of U.S. patent 12,291,499 for its CYB003 program, aimed at treating major depressive disorder (MDD). This patent secures the company's proprietary deuterated psilocin analog, including pharmaceutical compositions and oral dosage forms, ensuring exclusivity until 2041. Currently, Cybin is conducting a Phase 3 trial, dosing patients to evaluate the efficacy and safety of CYB003. The company underscores the critical role of intellectual property protection in advancing next-generation mental health therapies.

The CYB003 program represents a pioneering approach to mental health treatment, leveraging the therapeutic potential of psychedelics. With mental health conditions posing a significant global burden, the development of innovative treatments like CYB003 could offer new hope for millions suffering from MDD. Cybin's commitment to revolutionizing mental healthcare is supported by a network of esteemed partners and scientists, focusing on proprietary drug discovery and novel formulation approaches.

For further details on Cybin's groundbreaking work and the full press release, visit https://ibn.fm/61ZhG. Cybin's efforts in developing CYB003 and CYB004, a deuterated DMT molecule for generalized anxiety disorder, highlight the company's leadership in the psychedelic therapeutics space. Headquartered in Canada and operational across several countries, Cybin is at the forefront of addressing the unmet needs in mental health treatment.